Johnson & Johnson Q3
This article was originally published in The Rose Sheet
Executive SummaryWorldwide skin care sales advance 15% to $390 mil. in third quarter, led by Neutrogena, Aveeno, Clean & Clear brands, firm says in 1Oct. 15 sales and earnings release. Skin care sales in the U.S. rose 13% to $170 mil. and were up 17% to $169 mil. in international markets. "Continued strength of the overall product line, momentum associated with a broad range of new product offerings launched earlier this year and expanded growth of these equities outside the U.S. were the key drivers" of growth, according to J&J. Baby and kids care sales rose 4% worldwide to $300 mil., reflecting strong sales outside the U.S. of skin care and wipes products. Domestic baby care sales declined 3% to $68 mil., depressed by divestiture of Healthflow and Sippy Cup businesses...
You may also be interested in...
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.
First Circuit reverses dismissal of direct purchasers' suit alleging improper listing of patent on device drive mechanism delayed competition; district court to decide if this constitutes antitrust violation.
Brands unfairly attacked by powerful influencers could raise the subject with the US Federal Trade Commission, which is asking for comments on its “Endorsement Guides."